Study for People With Excess Body Weight and Knee Osteoarthritis

osteoarthritis, obesity

Are you Struggling With Obesity and Knee Pain Caused by Osteoarthritis?

This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Would you like to take part?

As a volunteer in a research study, you’ll receive study-related medical care from the study doctor and regular follow-up of your health to monitor the effectiveness of the care you’ll receive. The results of this research will be used to find out if the investigational medication being studied will be of benefit to others struggling with obesity and osteoarthritis related pain, and whether it will be made widely available to all Canadians trying to manage these conditions. Study volunteers are an important part of moving medical care forward.

You may qualify to participate in this study if you:

Are male or female (sex at birth)
Are age 18 years or above at the time of signing the informed consent
Have a clinical diagnosis of knee osteoarthritis (OA) (American College of Rheumatology criteria) with radiographic changes (Kellgren Lawrence [KL] grades 2 to 4 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg
Have symptomatic knee OA with first appearance of pain in the target knee > 90 days prior to screening and pain in the target knee for > 15 days over the prior 30 days
Have a willingness to complete a 72-hour washout period of analgesics before all visits involving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire (acetaminophen 4 grams (g)/day is allowed as rescue medication up until 24 hours before those visits)

You may not qualify to participate if you:

Have glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening
Have a history of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records
Have received treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening
Have any joint prosthesis or joint replacement in target knee
Have had arthroscopy or injections into target knee within the last 90 days prior to screening
Have any other joint disease in target knee including gout and pseudogout

There are other eligibility requirements that the study doctor will review. Only the study doctor can finally determine whether you are eligible to participate in the study or not.

Click the JOIN button if you think you might be eligible for this study.

All information about you will be kept confidential and will never be used or disclosed for any purpose not described in our Privacy Policy.

After providing us with your contact information, a research professional will get in touch to further assess your eligibility, answer any questions you have about the study, and determine if you qualify for participation.

Click the JOIN button if you think you might be eligible for this study.

Please complete the form below with your contact information.

Terms and Conditions

All information about you will be kept confidential and will never be used or disclosed for any purpose not described in our Privacy Policy.

After providing us with your contact information, a research professional will get in touch to further assess your eligibility, answer any questions you have about the study, and determine if you qualify for participation.